<DOC>
	<DOCNO>NCT00639327</DOCNO>
	<brief_summary>The purpose study compare overall survival test arm ( CPT-11/S-1 combination ) control arm ( CPT-11 alone ) subject S-1 refractory advance gastric cancer .</brief_summary>
	<brief_title>Second Line Chemotherapy S-1 Refractory Advanced Gastric Cancer</brief_title>
	<detailed_description>Standard chemotherapy advance gastric cancer ( AGC ) US Cisplatin/5-FU ( CF ) docetaxel/CF ( DCF ) , Europe epirubicin/CF ( ECF ) epirubicin/oxaliplatin/ capecitabine ( EOX ) . Until 2006 , evidence standard chemotherapy AGC Japan . In 2007 , result JCOG9912 trial ( 5-FU alone vs. CPT-11/CDDP v S-1 ) SPIRITS trial ( S-1 alone vs. S-1/CDDP ) , S-1/CDDP regard new standard regimen Japan . In 2008 , result TOP-002 trial ( s-1 alone vs. S-1/CPT-11 ) , S-1/CPT-11 could show superiority S-1 alone . One phase III trial , JACCRO GC-03 trial ( S-1 alone vs. S-1/docetaxel , NCT00287768 ) ongoing . However , position CPT-11 treatment AGC regard second-line . In Japan controversy treatment S-1 refractory gastric cancer . The controversy continue S-1 ( like FOLFOX FOLFIRI ) second-line . After successful adjuvant S-1 result ( ACTS-GC trial ) , problem occur patient recurrent adjuvant S-1 . Then , conduct phase II/III trial CPT-11 without S-1 treatment first-line S-1 refractory AGC .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically proven inoperable advanced gastric adenocarcinoma ( include adenocarcinoma gastroesophageal junction ) relapse gastric adenocarcinoma Subjects must able take orally Subjects must confirm PD status picture diagnosis firstline chemotherapy use S1 alone , S1 + Cisplatinum S1 + taxane , except S1 + CPT11 Within 4 week diagnosis PD Total dosage S1 firstline 2,240mg/m2 S1 alone treatment , 1,680mg/m2 S1 combination ECOG performance status ≤ 1 Follow Age 20 Life expectancy estimate 12 week Hgb ≥ 8 g/dL , WBC 4,00012,000/mm3 , ANC ≥ 2,000/mm3 , platelet ≥ 100,000/mm3 Creatinine ≤ upper normal limit ( UNL ) Total bilirubin ≤ 1.5 X UNL Written inform consent S1 + CPT11 employ firstline Any cytotoxic agent therapy , immunotherapy , radiationtherapy After S1 adjuvant Suspended case adverse event S1 S1 combination Excessive amount ascites require drainage Known brain metastasis History hypersensitivity fluoropyrimidines CPT11 Pregnancy lactation woman , woman suspect pregnancy men willing get pregnant Active double cancer Gastrointestinal bleeding Any subject judge investigator unfit reason participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>Second line chemotherapy</keyword>
	<keyword>Refractory S-1</keyword>
	<keyword>irinotecan</keyword>
	<keyword>S-1 Irinotecan Combination</keyword>
	<keyword>Phase III study</keyword>
</DOC>